Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 KWIKPEN versus NOVOLOG MIX 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 KWIKPEN versus NOVOLOG MIX 50 50.
HUMALOG MIX 75/25 KWIKPEN vs NOVOLOG MIX 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by promoting peripheral glucose uptake (especially in muscle and adipose tissue) and inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling pathways.
Insulin analog with rapid onset of action due to substitution of amino acid proline with aspartic acid at position B28, facilitating faster dissociation from hexamers into monomers after subcutaneous injection. Biphasic formulation containing 50% insulin aspart protamine (intermediate-acting) and 50% insulin aspart (rapid-acting).
Subcutaneous injection, individualized based on metabolic needs. Typical adult dose: 0.5-1.0 units/kg/day divided into preprandial doses. Administer within 15 minutes before a meal.
Subcutaneous injection. Typical adult dose: 0.5 to 1 unit/kg/day divided into two injections (with breakfast and dinner). Dose is individualized based on blood glucose levels and patient needs.
None Documented
None Documented
4-6 minutes for insulin lispro (rapidly absorbed and cleared); terminal elimination half-life of insulin lispro is approximately 1 hour (reflecting dissociation from insulin receptors). Clinical context: the brief half-life allows for rapid dose adjustments and reduced risk of late hypoglycemia.
6-8 hours (terminal half-life of protamine-bound fraction; free insulin component half-life ~4-5 minutes).
Renal: 100% (metabolized to inactive metabolites; metabolites excreted via kidneys). Biliary/fecal: negligible.
Renal: 50-60% as intact insulin, 30-40% as metabolites; biliary/fecal: minimal (<1%).
Category C
Category C
Insulin Analog
Insulin Analog